| Title | Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival. |
| Publication Type | Journal Article |
| Year of Publication | 1994 |
| Authors | Qin L, Chavin KD, Lin J, Yagita H, Bromberg JS |
| Journal | J Exp Med |
| Volume | 179 |
| Issue | 1 |
| Pagination | 341-6 |
| Date Published | 1994 Jan 01 |
| ISSN | 0022-1007 |
| Keywords | Animals, Antibodies, Monoclonal, Antigens, CD, Antigens, Differentiation, T-Lymphocyte, CD2 Antigens, CD48 Antigen, Drug Synergism, Female, Graft Survival, Heart Transplantation, Lymphocyte Culture Test, Mixed, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Inbred CBA, Receptors, Immunologic, T-Lymphocytes, Cytotoxic, Transplantation, Homologous |
| Abstract | Indefinite graft survival was obtained with murine cardiac allografts using the combined administration of monoclonal antibodies (mAbs) directed against the receptor ligand pair CD2-CD48. Although each antibody could prolong graft survival when given alone, neither resulted in the indefinite graft survival seen with the combination. Combined mAb administration is associated with inhibition of T cell priming and help and subsequent cytotoxic T lymphocyte generation. This indicates that the interaction between CD2 and its ligand is important for antigen priming and recognition, and combined mAbs may prove to be a useful therapeutic regimen for transplantation. |
| DOI | 10.1084/jem.179.1.341 |
| Alternate Journal | J Exp Med |
| PubMed ID | 7903681 |
| PubMed Central ID | PMC2191341 |
| Grant List | AI-32655 / AI / NIAID NIH HHS / United States |
Related Faculty:
Lihui Qin, M.D., Ph.D.